Metabolic Heterogeneity in Diffuse Large B-Cell Lymphoma Cells Reveals an Innovative Antimetabolic Combination...

Area of Science:

• Oncology
• Metabolic Biology
• Pharmacology

Background:

• Diffuse large B-cell lymphoma (DLBCL) is a common, aggressive non-Hodgkin lymphoma, particularly challenging in relapsed or refractory (R/R) cases.
• Malignant cells exhibit metabolic reprogramming, presenting therapeutic vulnerabilities.
• Targeting metabolic pathways is a strategy to improve outcomes for R/R DLBCL patients.

Purpose of the Study:

• To investigate the combined effects of metformin and L-asparaginase on DLBCL cell metabolism and survival.
• To explore the potential of this drug combination as a novel therapeutic strategy for R/R DLBCL.

Main Methods:

• Utilized Nuclear Magnetic Resonance (NMR) spectroscopy to analyze metabolic changes in DLBCL cells treated with metformin and L-asparaginase.
• Assessed impacts on lipid metabolism, glycolysis, glutaminolysis, TCA cycle, and antioxidant responses.
• Evaluated apoptosis induction via FACS analysis and examined effects on mTORC1 and MAPK signaling pathways.

Main Results:

• The combination therapy significantly sensitized DLBCL cells to apoptosis, irrespective of their metabolic profile.
• NMR revealed broader metabolic disturbances with the combination compared to single agents, disrupting lipid metabolism and counteracting metformin's pro-glycolytic effects.
• The combination reduced glycolysis and glutaminolysis, affected the TCA cycle and antioxidant responses, and interfered with mTORC1 and MAPK signaling.

Conclusions:

• Metformin and L-asparaginase combination therapy targets multiple metabolic pathways crucial for DLBCL cell survival.
• This synergistic approach demonstrates potential as a novel therapeutic strategy for patients with relapsed or refractory DLBCL.